Background New antituberculosis regimens are urgently needed to shorten tuberculosis
treatment. Following on from favourable assessment in a 2 week study, we investigated a …

Background New anti-tuberculosis regimens that are shorter, simpler, and less toxic than
those that are currently available are needed as part of the global effort to address the …

Background Tuberculosis is the world's leading infectious disease killer. We aimed to
identify shorter, safer drug regimens for the treatment of tuberculosis. Methods We did a …

Background New drugs, but also shorter, better-tolerated regimens are needed to tackle the
high global burden of tuberculosis complicated by drug resistance and retroviral disease …

Background New treatments are needed to shorten the time required to cure tuberculosis
and to treat drug-resistant strains. The fluoroquinolone moxifloxacin is a promising new …

Background Outcomes of treatment of tuberculosis patients with regimens including
pretomanid have not yet been systematically reviewed. Objectives To appraise existing …

Abstract Moxifloxacin, an 8‐methoxy quinolone, is an important drug in the treatment of
multidrug‐resistant tuberculosis and is being investigated in novel drug regimens with …

Background Early-phase and preclinical studies suggest that moxifloxacin-containing
regimens could allow for effective 4-month treatment of uncomplicated, smear-positive …

BACKGROUND: Treatment for TB is lengthy and toxic, and new regimens are needed.
METHODS: Participants with pulmonary drug-susceptible TB (DS-TB) were randomised to …

Background In contrast to drug-sensitive tuberculosis, the guidelines for the treatment of
multi-drug-resistant tuberculosis (MDR-TB) have a very poor evidence base; current …